Ptc Therapeutics, Inc.

Daifuku Co., Ltd.

Sumitomo Pharma Co., Ltd.

Kazuto Mori

Hiroyuki Kitano

Tomoyuki Furuta

Kouichi Ikawa

Yohei Kobayashi

Hajime Seki

Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): or a pharmaceutically acceptable salt thereof wherein Xrepresents CRor N, Xrepresents CRor N, Xrepresents CRor N, Xrepresents CRor N, Y represents optionally substituted Calkyl, an optionally substituted Calicyclic group, an optionally substituted 4- to 10-membered nitrogen-containing non-aryl heterocycle, optionally substituted Caryl, or optionally substituted 5- to 10-membered heteroaryl, Z represents optionally substituted 6- to 10-membered heteroaryl, and R, R, R, and Reach independently represent a hydrogen atom, halogen, cyano, optionally substituted Calkyl, optionally substituted Calkoxy, or the like.

2-heteroaryl aminoquinazolinone derivative

Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotropic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntington disease, Parkinson disease, Alzheimer disease, myocardial infarction, cerebral infarction, diseases related to aging, diabetes, alcoholic liver injury, chronic obstructive pulmonary disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and the like, wherein the compound is represented by formula (1), or reduced forms thereof, or pharmaceutically acceptable salts thereof.

2-substituted amino-naphth (1,2-d) imidazol-5-one compounds of pharmaceutically acceptable salts thereof

Provided is a 2-heteroaryl aminoquinazolinone derivative, which is a compound represented by formula (1): 

Provided herein are therapeutic and/or prophylactic compounds for mitochondrial or oxidative stress diseases such as cancer, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, Machado-Joseph disease, spinocerebellar ataxia, Huntington disease, Parkinson disease, Alzheimer disease, myocardial infarction, cerebral infarction, diseases related to aging, diabetes, alcoholic liver injury, chronic obstructive pulmonary disease, mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), and the like, wherein the compound is represented by formula (1), or reduced forms thereof, or pharmaceutically acceptable salts thereof. 

2-substituted amino-naphth (1,2-d) imidazol-5-one compounds or pharmaceutically acceptable salts thereof

A facility control system comprises a selection processing portion that selects, based on a manual operation and when an abnormal condition occurs in a second-layer computer that issues a task command to a first-layer program which issues an apparatus operating command to an apparatus controller, whether to cause a first-layer computer to execute a second-layer program that had been executed by the second-layer computer, and a substitute command output processing portion which outputs a substitute command in accordance with selection information selected by the selection processing portion. The first-layer computer executes the second-layer program that had been executed by the second-layer computer in which the abnormal condition occurred based on a substitute command outputted by the substitute command output processing portion.

Facility control system and facility control method

A facility control system comprises a selection processing portion that selects, based on a manual operation and when an abnormal condition occurs in a first-layer computer that executes a first-layer program which issues an apparatus operating command to an apparatus controller, whether to cause a second-layer computer to execute the first-layer program that had been executed by the first-layer computer, and a substitute command output processing portion which outputs a substitute command in accordance with selection information selected by the selection processing portion. The second-layer computer executes the first-layer program that had been executed by the first-layer computer in which the abnormal condition occurred based on a substitute command outputted by the substitute command output processing portion.

Growing community of inventors

Osaka, Japan

Kazuto Mori